Active infection requiring intravenous (IV) antibiotics Active infection requiring intravenous antibiotics within 1 week of study enrollment (day 1). Active infection requiring intravenous antibiotics at cycle 1 day 1 Active systemic infection requiring intravenous antibiotics within 2 weeks of treatment start Patients with any unstable medical issue (including cardiac issues as above, active treatment for symptomatic pulmonary embolism, cerebrovascular accident [CVA], renal or hepatic insufficiency, active infection/sepsis requiring intravenous [IV] antibiotics) Ongoing or active infection; the requirement for intravenous (IV) antibiotics is considered active infection Ongoing active infection; the requirement for intravenous (IV) antibiotics is considered active infection Active infection (infection requiring intravenous antibiotics) Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1, Cycle 1 Active infection requiring intravenous antibiotics at week 1 day 1 Active serious infection not controlled by oral or intravenous antibiotics Clinically significant active infection requiring intravenous antibiotics (=< 14 days prior to registration) Active infection requiring intravenous antibiotics (must be completed prior to registration) Infection requiring intravenous antibiotics that was completed < 1 week of study enrollment (day 1) with the exemption of prophylactic antibiotics for long line insertion or biopsy Active infection (requiring oral or intravenous antibiotics or antiviral therapy). Active serious infection not controlled by oral or intravenous antibiotics. Patients with active systemic infections requiring intravenous antibiotics within 1 week prior to enrollment Active infection requiring intravenous antibiotics (antibiotics should have been completed prior to registration) Active serious infection not controlled by oral or intravenous antibiotics. Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization. Clinically significant active infection requiring intravenous antibiotics =< 14 days prior to registration Any uncontrolled active systemic infection requiring intravenous (IV) antibiotics Active infection requiring intravenous antibiotics Evidence of ongoing or active infection requiring intravenous antibiotics; Active infection requiring intravenous antibiotics within 7 days before enrollment Active infection requiring intravenous antibiotics at the time of registration Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration Unstable systemic disease in the opinion of the treating physician, for example active infection requiring intravenous (IV) antibiotics Serious active infection requiring intravenous (IV) antibiotics Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration Patients should be free of active infection requiring intravenous antibiotics Active serious infection not controlled by oral or intravenous antibiotics Patients must be free of systemic infection requiring intravenous (IV) antibiotics at the time of registration; patients must be off IV antibiotics for at least 7 days prior to registration Active infection requiring oral or intravenous antibiotics Patients with active chronic or current infections requiring oral or intravenous antibiotics are NOT eligible for enrollment to the study until resolution of the infection and completion of therapeutic antibiotics Active clinically serious infection requiring intravenous antibiotics at the time of study entry (CTCAE Grade 2) Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization. Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization Serious infection requiring treatment with intravenous antibiotics at the time of study entrance, or an infection requiring intravenous therapy within 7 days prior. Serious infection requiring hospitalization or intravenous (IV) antibiotics within 14 days prior to enrollment Active infection requiring intravenous antibiotics At least 7 days beyond any infection requiring intravenous antibiotic use (Oral\n antibiotics may be administered prophylactically as clinically indicated) Patients have an active infection and require intravenous (IV) or oral antibiotics Receipt of intravenous antibiotics for infection within 7 days prior to enrollment Patients with active infection and requiring intravenous (IV) or oral antibiotics Serious active infection requiring intravenous (i.v.) antibiotics at enrollment Active systemic infections requiring intravenous antibiotics Patients must not have uncontrolled active systemic infection requiring intravenous antibiotics Patients with active systemic infection requiring intravenous antibiotics Serious active infection requiring intravenous antibiotics and/or hospitalization at study entry Any infection requiring ongoing intravenous antibiotics for management Patient has evidence of a serious active infection (e.g., infection requiring treatment with intravenous antibiotics). Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization Active (acute or chronic) or uncontrolled severe infections requiring intravenous antibiotics Have an ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection. Serious infection requiring treatment with intravenous antibiotics at the time of study entrance, or an infection requiring intravenous therapy within 7 days prior to the first dose of study treatment. Receipt of intravenous (IV) antibiotics for infection within 7 days prior to enrollment into the study Patients with active infection and requiring intravenous (IV) or oral antibiotics Infection requiring intravenous antibiotics within 14 days before the first dose of study drug Concurrent severe and/or uncontrolled medical disease including, but not limited to, ongoing or active infection requiring intravenous antibiotics, bowel obstruction Concurrent severe and/or uncontrolled medical disease including, but not limited to, ongoing or active infection requiring intravenous antibiotics Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics Serious, active infections requiring treatment with intravenous (IV) antibiotics Active infection, uncontrolled with intravenous antibiotics Patients with active infection requiring intravenous (IV) antibiotics within 2 weeks of registration Active systemic infections requiring intravenous antibiotics Active serious infection not controlled by oral or intravenous antibiotics Patients have an active infection and require intravenous (IV) or oral antibiotics Active infection requiring intravenous antibiotics Active infection requiring intravenous (IV) antibiotics Any uncontrolled active systemic infection that requires treatment with intravenous (IV) antibiotics Presence of an infection that requires intravenous antibiotics Active infection requiring intravenous antibiotics. Current acute infection requiring intravenous antibiotics Uncontrolled medical illness such as infection requiring intravenous antibiotics Active infection requiring intravenous (IV) antibiotics Known active infection requiring intravenous (IV) or oral anti-infective treatment History of any infection requiring hospitalization or intravenous antibiotics within 2 weeks before enrollment. The patient has received intravenous administration of antibiotics within 2 weeks prior to first study treatment or oral antibiotics within 1 week prior to first study treatment. Active systemic infections requiring intravenous antibiotics Use of intravenous antibiotics within the last 6 months Serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring intravenous (IV) antibiotics Diagnosis of an infection requiring intravenous (IV) antibiotics 14 days prior to registration Active systemic infection requiring ongoing intervention, including but not limited to oral and intravenous antibiotics, anti-fungals, anti-parasites, anti-virals Active infection requiring oral or intravenous antibiotics The participant has an active infection (requiring intravenous [IV] antibiotics), including tuberculosis. Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or intravenous (IV) antibiotics within 2 weeks prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to registration; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Treatment with oral or intravenous (IV) antibiotics within 2 weeks prior to Day 1 of Cycle 1 Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment, except prophylactic antibiotics Received oral or intravenous (IV) antibiotics within 2 weeks prior to Cycle 1, Day 1. Participants receiving prophylactic antibiotics (for prevention of a urinary tract infection chronic obstructive pulmonary disease) are eligible Received therapeutic oral or IV antibiotics within 2 weeks prior to Day 0; Therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to first day of study treatment:\r\n* Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible GENERAL: Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1.\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible. Treatment with oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1 Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to start of study treatment.\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible. Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study treatment:\r\nPatients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible Received oral or IV antibiotics for an infection within 2 weeks prior to the first study treatment. Subjects receiving prophylactic antibiotics are eligible Treatment with therapeutic oral or IV antibiotics within 14 days prior to initiation of study treatment; patients receiving prophylactic antibiotics (e.g. for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to study treatment; but patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1 a) Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Oral or IV antibiotics within 2 weeks prior to enrollment Received therapeutic oral or IV antibiotics within 1 week prior to cycle 1 day 1\r\n* Subjects receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible Received oral or IV antibiotics =< 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Oral or IV antibiotics within 2 weeks prior to enrollment Oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1 Patients who have received oral or IV antibiotics within 2 weeks before initiation of study treatment; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1 (Patients receiving prophylactic antibiotics [e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease] are eligible.) Received oral or IV antibiotics within 2 weeks prior to week 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received therapeutic oral or IV antibiotics within 2 weeks prior to first dosing. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment; patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study Received therapeutic oral or IV antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Therapeutic oral or IV antibiotics within 2 weeks prior to cycle 1, day 1\r\n* Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1 Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1 for treatment of active infection (patients receiving prophylactic antibiotics [e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease] are eligible) Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to the first dose of study treatment Received IV antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible Received therapeutic oral or IV antibiotics within 4 weeks prior to Cycle 1, Day 1 (except for tumor fever) Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to first day of study treatment; patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1 Received oral or IV antibiotics within 14 days prior to Day 1 Active infection or chronic infection requiring chronic suppressive antibiotics Active infection requiring treatment with antibiotics Patients must not have a serious intercurrent illness, including ongoing or active infection requiring parental antibiotics Active infection or chronic infection requiring chronic suppressive antibiotics. Active infections requiring antibiotics, physician monitoring or recurrent fevers >100.4?F (38.0?C) associated with a clinical diagnosis of active infection Active infection requiring IV antibiotics at day 1 of cycle 1 Active infection requiring IV antibiotics within 2 weeks of study dose No active infection requiring antibiotics Active infection requiring antibiotics Active infection requiring iv antibiotics at day 1 of cycle 1 EXCLUSION - PROCUREMENT: Active infection requiring antibiotics Active infection requiring IV antibiotics on Cycle 1, Day 1 If they have a major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics Currently using antibiotics and/or anti fungal agent (however, topical antibiotics are permitted). Active infection requiring systemic antibiotics or antifungals within 7 days prior to first dose of study drug; exception: tetracycline family antibiotics (tetracycline, doxycycline, minocycline) administered for the management of cetuximab-related rash may be continued per the investigator’s judgment Active infection requiring the use of systemic antibiotics Participant has an active infection requiring IV antibiotics Active infection requiring systemic antibiotics within 2 weeks prior to cycle 1, day 1; prophylactic short-term antibiotics will be allowed Has an active infection requiring systemic therapy with IV antibiotics Presence of an serious illness, uncontrolled illness, or active infection requiring IV antibiotics. Active infection or chronic infection requiring chronic suppressive antibiotics Have active infection requiring antibiotics Has an active infection requiring systemic antibiotics within 10 days of registration Patients should not be on antibiotics for any infection but post operative antibiotics are allowed if used prophylactically but should be completed prior to starting RT Known HIV-1 or any active infection requiring IV antibiotics Major systemic infection requiring antibiotics 72 hours or less prior to first dose of study drug Active infection requiring IV antibiotics 7 days before enrollment Patients must not have an active major systemic infection requiring systemic antibiotics 72 hours or less prior to the first dose of study drug Patients should be free of active infection requiring antibiotics Active infection requiring systemic therapy with IV antibiotics Active infection or chronic infection requiring chronic suppressive antibiotics. Active infection requiring antibiotics Active infection not adequately responding to appropriate antibiotics (i.e. ongoing temperatures of >= 38 degree Celsius) Active infection requiring antibiotics Active infection requiring treatment with systemic antibiotics or systemic anti-fungal agents Active infection or chronic infection requiring chronic suppressive antibiotics. Treated with antibiotics for infection within one week prior to study entry. If they have a major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug Treatment with antibiotics within 2 weeks (14 days) of dosing Subjects with an active infection requiring antibiotics or at an increased risk of latent infection that may affect safe study participation Subjects with active infection requiring IV antibiotics within 2 weeks of study enrollment (day 1) are excluded Active infection-must be afebrile and off antibiotics Participants with an active infection requiring antibiotics are excluded (a positive screening urinalysis may be repeated) Uncontrolled infection requiring active treatment (systemic antibiotics, anti-virals, or anti-fungals) within 14 days Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment unless the patient is felt to have fully recovered and any antibiotics that are continued are either beta lactam antibiotics or are specifically allowed on study Active infection or chronic infection requiring chronic suppressive antibiotics Evidence of any active infection requiring hospitalization or IV antibiotics within 2 weeks prior to study enrolment. Active infection, or chronic infection requiring chronic suppressive antibiotics. Active pulmonary infection not responsive to conventional antibiotics Any known HIV infection or AIDS or any concurrent infection requiring IV antibiotics Has an active infection requiring systemic antibiotics within 7 days of registration Active infection or antibiotics within 48 hours prior to study Active infection within the 14 days prior to randomization requiring systemic antibiotics Active infection requiring treatment with IV antibiotics or hospitalized for treatment of an active infection in 4 wks prior to starting dose of AMG 592. Presence of acute active infection requiring antibiotics Serious active infection requiring i.v. antibiotics and/or hospitalization at study entry Patients with an active infection requiring antibiotics Active infection not adequately responding to appropriate antibiotics (i.e. ongoing temperatures of >= 38 degree Celsius) Patients should be free of active infection requiring antibiotics Uncontrolled infection requiring ongoing antibiotics Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics Active infection involving IV antibiotics within 2 weeks prior to C1D1 Active uncontrolled serious infection or sepsis at study enrollment; patients receiving antibiotics for infections that are under control may be included in the study Active infection involving IV antibiotics within 2 weeks prior to C1D1 Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics Has an active infection requiring antibiotics Ongoing or active infection requiring parental antibiotics on Day 1 Known active infection requiring antibiotics within 7 days of the start of treatment (day 0) Ongoing or active infection requiring IV antibiotics Active infection requiring antibiotics Treatment with antibiotics within 2 weeks (14 days) of dosing. Has an active infection requiring systemic antibiotics. Active infection requiring antibiotics Ongoing or active infection requiring antibiotics; Has an active infection requiring systemic antibiotics Active infection requiring IV antibiotics Active infection requiring antibiotics Active infection requiring antibiotics Active infection requiring antibiotics Active infection requiring IV antibiotics within 2 weeks prior to screening Active infection requiring iv antibiotics Uncontrolled infection requiring systematic antibiotics within 14 days before the first dose of study drug Has uncontrolled infection requiring systematic antibiotics Active infection requiring (IV) antibiotics within 2 weeks of study enrollment Active infection requiring IV antibiotics Any infection requiring antibiotics within the past 2 weeks. Serious infection requiring antibiotics Pneumonia requiring antibiotics at the time of study enrollment Patients with a previous or current line infection are ineligible until 14 days after the completion of antibiotics Active infection requiring antibiotics No use of antibiotics in the previous 3 months; or current regular use of antibiotics Patients should be free of active infection requiring antibiotics A non?urologic bacterial infection requiring active treatment with antibiotics Patients with active and/or uncontrolled infections or who are still recovering from an infection\r\n* Actively febrile patients with uncertain etiology of febrile episode\r\n* All antibiotics should be completed at least 1 week (7 days) prior to collection\r\n* No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics\r\n* Note: Use of antibiotics for pre-operative prophylaxis is not an exclusion The participant has an active infection (requiring I.V antibiotics), including tuberculosis.